预约演示

更新于：2025-07-20

Hydrocodone bitartrate

重酒石酸氢可酮

更新于：2025-07-20

概要

基本信息

简介Hydrocodone bitartrate是一种阿片类止痛药，通常被称为“氢可酮”。其化学名为4,5(alpha)-epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5) 或morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5 alpha)-, [R (R*, R*)]-2,3-dihydroxybutanedioate (1:1),hydrate (2:5)。氢可酮是美国用于急性和慢性疼痛的最常用药物，2012年的处方量超过1.35亿。由于其易获取性和滥用模式，氢可酮被认为是引起滥用和误用的阿片类药物的主要驱动力。其机制是通过刺激阿片受体发挥镇痛作用。

药物类型

小分子化药

别名

酒石酸氢可酮、AFI-001、ATLP-03

+ [9]

靶点

Opioid receptors

作用方式

激动剂

作用机制

Opioid receptors激动剂(阿片样受体激动剂)

治疗领域

神经系统疾病其他疾病

在研适应症

疼痛

非在研适应症

慢性骨关节炎慢性疼痛终末期肾脏病+ [3]

原研机构-

在研机构

Purdue Pharma LP

非在研机构

Teva Branded Pharmaceutical Products R&D, Inc.

Societal CDMO Gainesville LLC

Zogenix, Inc.

+ [1]

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (2013-10-25),

疼痛

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C22H29NO10

InChIKeyZICRJLQTAUVSDU-NSJZFRMTSA-N

CAS号34195-34-1

关联

项与重酒石酸氢可酮相关的临床试验

NCT06780202

/ Recruiting临床2期IIT

Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients

This clinical trial aims to determine the effects of a 6-day low-dose methylprednisolone course on pain, nausea, and total opioid consumption in patients undergoing foot and ankle surgeries.
The secondary objective of the study is to determine and monitor the effects of the course on complications following surgery and patient-reported outcomes

开始日期2025-01-27

申办/合作机构

Emory University

NCT06585163

/ Not yet recruiting临床1期

A Phase 1, Randomized, Double-blind, Crossover Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of QEV-817 Oral Suspension in Healthy Volunteers

This study has been designed to assess the safety, tolerability, and pharmacokinetics of a therapeutic dose of hydrocodone bitartrate with and without an oral dose of doxapram hydrochloride in healthy volunteers who are naltrexone-blocked.

开始日期2024-09-01

申办/合作机构

Quivive Pharma, Inc.

[+1]

NCT06232577

/ Active, not recruiting临床2期IIT

5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial

To compare 2 different models for prescribing opioid pain medication to provide better pain control to participants with an abdominal cancer who are having surgery.

开始日期2024-03-27

申办/合作机构

The University of Texas MD Anderson Cancer Center

100 项与重酒石酸氢可酮相关的临床结果

登录后查看更多信息

100 项与重酒石酸氢可酮相关的转化医学

登录后查看更多信息

100 项与重酒石酸氢可酮相关的专利（医药）

登录后查看更多信息

1,619

项与重酒石酸氢可酮相关的文献（医药）

2025-12-01·HISTOCHEMISTRY AND CELL BIOLOGY

Bioactive and degradable collagen-based hydrogel encapsulated with microspheres containing basic fibroblast growth factor (bFGF) and interleukin (IL)-10 promotes recovery following traumatic spinal cord injury in rats

Article

作者: Hjazi, Ahmed

Traumatic spinal cord injury (TSCI) is a severe event within the central nervous system, leading to the impairment of sensory and motor abilities at the injury site in the spinal cord. Current therapeutic approaches offer limited efficacy in improving recovery, underscoring the need to explore alternative treatments. In the present study, we examined the sustained co-delivery of basic fibroblast growth factor (bFGF) and interleukin-10 (IL-10), encapsulated in microspheres and incorporated into a collagen-based hydrogel, for its effects on the healing of TSCI in an animal model. Seventy-five male Sprague Dawley rats were randomly divided into five groups: control, TSCI, hydrogel, microspheres, and hydrogel loaded with microspheres (Hyd + Micro). Tissue samples were collected from the injury site for further evaluation. Compared to the TSCI group, treatment groups demonstrated notably higher numerical densities of neurons and greater motor neuron health, as well as increased levels of vascular endothelial growth factor (VEGF) and antioxidative factors (catalase [CAT], glutathione [GSH], and superoxide dismutase [SOD]), and improved neurological function scores (electromyography [EMG], Basso-Beattie-Bresnahan (BBB) test, and narrow beam-walking test [NBT]). These changes were most pronounced in the Hyd + Micro group. The treatment also led to a significant decrease in the counts of apoptotic and glial cells, alongside reduced levels of malondialdehyde (MDA) and pro-inflammatory cytokines (IL-1β and TNF-α), with the most notable enhancements seen in the Hyd + Micro group. These findings indicate that the co-delivery of bFGF and IL-10 encapsulated in microspheres within a collagen-based hydrogel provides enhanced neuroprotective effects in TSCI animal models.

2025-08-01·Foot & ankle specialist

Opioid Prescribing Trends Among Workers’ Compensation Patients Undergoing Foot and Ankle Surgery

Article

作者: Murray, Richard D. ; Wilson, Andrew W. ; Miles, Daniel T. ; Goodwin, Tyler M. ; Doty, Jesse F.

Background:

The purpose of this study was to evaluate opioid usage and prescribing trends among workers’ compensation (WC) patients who underwent foot or ankle operative procedures compared with a control group.

Methods:

A retrospective review was conducted for WC and non-WC patients who underwent foot or ankle procedures in a single academic orthopaedic surgery practice. Outcome measures were total morphine milligram equivalents (MME) and number of opioid prescriptions.

Results:

A total of 118 patients were identified, including 51 patients in the WC group and 67 in the non-WC group. After index surgery, 67% (34 of 51) of WC patients had 2 or more additional opioid prescriptions compared to 39% (26 of 67) of non-WC patients (odds ratio [OR], 3.1; 95% confidence interval [CI], 1.4-6.7; P = .003). Collectively, there were greater prescriptions of oxycodone MME (P = .002) and hydrocodone MME (P = .07) in the WC cohort.

Conclusions:

Workers’ compensation patients seem to be prescribed and consume opioids at a higher rate postoperatively. It is important for treating physicians to be aware of these trends, and discussions with patients regarding expected opioid use when planning surgical intervention may be beneficial. Physicians may need to set expectations preoperatively and suggest there are limits on the amount of opioids that can safely be prescribed.

Level of Evidence::

Level III, Retrospective cohort study, Prognostic

2025-07-01·PAIN

Distribution of opioid analgesics by community racial/ethnic and socioeconomic profiles, 2011-2021

Article

作者: Paice, Judith A. ; Bao, Yuhua ; Zhang, Fang ; Zhang, Hao ; Hu, Ju-Chen ; Rosa, William E. ; Chakraborty, Promi ; Bruera, Eduardo ; Portenoy, Russell ; Zhang, Yiye ; Reid, M. Carrington ; Tamimi, Rulla M.

Abstract:

Rapid declines in opioid analgesics dispensed in American communities since 2011 raise concerns about inadequate access to effective pain management among patients for whom opioid therapies are appropriate, especially for those living in racial/ethnic minority and socioeconomically deprived communities. Using 2011 to 2021 national data from the Automated Reports and Consolidated Ordering System and generalized linear models, this study examined quarterly per capita distribution of oxycodone, hydrocodone, and morphine (in oral morphine milligram equivalents [MMEs]) by communities' racial/ethnic and socioeconomic profiles. Communities (defined by 3-digit-zip codes areas) were classified as “majority White” (≥50% self-reported non-Hispanic White population) vs “majority non-White.” Community socioeconomic deprivation was measured by quartiles of population-weighted Social Deprivation Index. Overall, majority non-White communities had at least 40% lower mean adjusted per capita distribution than majority White communities across all levels of socioeconomic deprivation. Among the least deprived communities, the adjusted mean per capita distribution was 46.0 (95% confidence interval [CI], 40.0-52.0) for majority non-White vs 82.8 (95% CI, 78.5-87.1) MMEs for majority White communities. Among the most deprived communities, the distribution was 78.0 (95% CI, 70.8-85.1) for majority non-White vs 134.4 (95% CI, 125.4-143.4) MMEs for majority White communities. The lower distribution in majority non-White communities was statistically significant across all socioeconomic deprivation levels and over all study years. Availability of commonly prescribed opioid analgesics was substantially lower in majority non-White communities than in majority White communities across all levels of socioeconomic deprivation. Policies governing opioid analgesic availability warrant careful consideration and potential adjustments.

项与重酒石酸氢可酮相关的新闻（医药）

2025-06-16

·药物分子设计

上海大学宋健等综述：精准识别多种分析物的碳基多变量化学传感器

研究背景在科技蓬勃发展的时代，化学传感器广泛应用于环境监测、工业生产、医疗诊断等诸多领域，对保障生活质量和推动产业发展意义重大。在环境监测中，精准检测空气中的有害气体浓度；在医疗诊断里，助力疾病的早期发现与诊断。然而，传统单变量传感器面对复杂化学环境时，易受共存分析物干扰，导致响应重叠，难以准确测量和识别多种化学组分。传感器阵列虽能在一定程度上解决问题，但材料修饰过程复杂，限制了实际应用。因此，开发高性能、多功能的化学传感器迫在眉睫，碳基多变量化学传感器应运而生，成为解决这一难题的关键所在。Applications of Carbon-Based Multivariable Chemical Sensors for Analyte RecognitionLin Shi, Jian Song*, Yu Wang, Heng Fu, Kingsley Patrick‑Iwuanyanwu, Lei Zhang*, Charles H. Lawrie*, Jianhua Zhang*Nano-Micro Letters (2025)17: 246https://doi.org/10.1007/s40820-025-01741-0本文亮点1. 回顾了碳基多变量化学传感器的基本原理和研究进展，特别聚焦于多种分析物的分类和识别。2. 详细讨论了以碳纳米管/石墨烯作为传感材料、以场效应晶体管作为变换器的碳基多变量化学传感器。3. 对多变量传感机制进行了全面分析，并总结了碳基多变量传感器的设计准则。内容简介上海大学宋健&张磊&张建华等聚焦于碳基多变量化学传感器，详细探讨了以碳纳米管/石墨烯为传感材料、场效应晶体管(FETs)为变换器的化学传感器。介绍了碳基材料的基本性质，如石墨烯和碳纳米管独特的结构赋予其高比表面积、高载流子迁移率等优异性能，还阐述了晶圆级器件的制备方法及应用情况。同时，分析了化学电阻型和FET型传感器的结构特点与制备工艺，介绍了响应/恢复时间、漂移、灵敏度等关键性能指标，以及主成分分析、线性判别分析等常用模式识别算法。文中深入剖析了多变量传感机制，并介绍了改变操作条件和从输出曲线提取特征这两种特征提取方案。此外，展示了碳基FET型化学传感器在多变量传感中的应用，包括多种气体识别和生物标志物识别等方面的成果。最后，总结了该传感器在复杂环境分析中具有的优势，并从优化传感材料、改进FET性能和发展模式识别算法等方面对未来研究方向进行了展望，旨在推动化学传感器技术取得进一步发展，使其能更好地应用于环境监测、医疗诊断等多个领域。图文导读I 化学传感器结构与原理演进本综述以图1为切入点，呈现化学传感器的发展轨迹。图1a的单变量传感器，仅能将敏感材料的单一物理化学性质变化转化为一种电参数，在复杂环境中，易受干扰，致使选择性和识别能力受限。图1b展示的传感器阵列，虽通过增加传感单元数量来提升检测能力，但面临数据处理复杂、多种敏感材料修饰繁琐及设备体积庞大等问题。而图1c的多变量传感器，采用对不同分析物具备多种响应机制的传感材料，并结合多变量变换器输出多个独立电参数，有效克服传统传感器的缺陷，显著增强在复杂环境中对多种分析物的识别能力，此结构创新是碳基多变量化学传感器的关键优势所在。图1. a单变量传感器、b传感器阵列和c多变量传感器的结构示意图。ΔT：温度，Δσ：电导率，Δφ：功函数，Δε：介电常数，ΔC：电容，ΔL：电感，ΔR：电阻，SM：传感材料，MonoT：单变量变换器，Vth：阈值电压，gm：跨导，SS：亚阈值斜率摆幅。II 碳基材料特性与微观结构碳纳米管和石墨烯作为关键传感材料，其独特结构和优异性能对传感器性能起着决定性作用。图2展示了这些材料的微观结构，图2a呈现了石墨烯、氧化石墨烯和还原氧化石墨烯从石墨剥离形成的三维结构示意图，图2b-d的高分辨率透射电镜图进一步揭示其微观特征，二维蜂窝状网络结构赋予它们大比表面积等优势。图2e形象的展示了碳纳米管由石墨烯片卷曲而成的结构，图2f-i呈现不同形态的碳纳米管，如单根碳纳米管及不同排列方式的碳纳米管网络。这些结构使碳纳米管具备高机械强度和优良电学性能，为传感器实现高灵敏度、高选择性检测奠定坚实基础。图2. a从石墨中分离出来的石墨烯、氧化石墨烯和还原氧化石墨烯的三维结构示意图。b石墨烯、c氧化石墨烯和d还原氧化石墨烯的高分辨率透射电子显微镜图。e由单层和多层石墨烯薄片卷成的单壁和多壁碳纳米管示意图。f单根碳纳米管的原子力显微镜图像。g垂直排列、h水平排列和i随机网络碳纳米管的扫描电子显微镜图像。III 传感器结构与性能评估指标图3聚焦于化学电阻式和场效应晶体管(FET)型化学传感器的结构与性能指标。图3a的化学电阻式传感器，依靠分析物与传感材料相互作用改变电极间电阻来实现检测，多变量输出通常从响应时间曲线中提取。图3b-f展示了FET型化学传感器的常见结构，包括顶栅、背栅和侧栅等，不同结构在稳定性、响应性和工艺兼容性等方面各有优劣。图3g和图3h分别为传感器的响应曲线和校准曲线，用于定义和理解响应时间、灵敏度等关键性能指标，这些指标是评估传感器性能的重要依据，有助于定量分析传感器在不同条件下的检测能力。图3. a化学电阻式传感器和五种场效应晶体管式化学传感器的结构示意图：b顶栅顶接触式、c顶栅底接触式、d背栅顶接触式、e背栅背接触式和f侧栅器件。g响应曲线和h校准曲线中反映传感性能的性能指标。i碳基场效应晶体管式化学传感器的制备工艺。IV 多变量传感机制与特征提取策略多变量传感机制是碳基多变量化学传感器的核心技术。图4展示该机制及相关特征提取方法。图4a揭示单变量传感器在干扰气体存在时，输出易受影响，难以准确检测目标气体。图4b和图4c则展示多变量传感器通过增加输出变量，在二维和三维空间中有效区分多种分析物的优势。图4d-f分别展示改变传感器操作条件(如光调制、栅极电压调制)以及从噪声光谱、响应时间曲线和FET转移特性曲线提取特征的方法。这些方法为获取丰富传感信息、实现多变量输出提供有效途径，进而增强传感器对复杂环境中多种分析物的识别能力。图4. a仅使用单个输出变量(Output #1)时，在干扰气体和目标气体之间观察到的响应重叠。传感器对干扰气体的响应：10 ppm干扰气体的响应会导致传感器产生异常输出(？)；20-30 ppm干扰气体的响应与1-2 ppm目标气体的响应产生重叠(×)；只有3 ppm目标气体能克服干扰(√)。b在二维传感平面上使用两个输出变量(Output #1和Output #2)的三种分析物的输出特性曲线。虽然三种分析物在Output #1中都显示出相同的响应，但它们在Output #2中显示出不同的模式，从而成功地进行了区分。c四种分析物在具有三个输出变量(Output #1、Output #2和Output #3)的三维传感空间中的输出特性曲线。更高维的传感空间显示出更强的分析物鉴别能力，能够识别更广泛的分析物种类。d使用光调制和e栅极电压调制提取输出变量。从f噪声频谱和g响应时间曲线中提取输出变量。h基于碳纳米管的FET型化学传感器传递特性曲线的四种变化模式，能够反映传感机理。i利用基于石墨烯的FET型化学传感器的狄拉克点偏移，进行COVID-19阴/阳性样本区分的示意图。V 碳纳米管基FET型多变量化学传感器应用实例图5展示基于碳纳米管的FET传感器在多变量传感中的应用。图5a为传感器阵列及沟道区域的SEM图像，图5b详细呈现从其转移特性曲线提取11个特征参数的方法。对比图5c和图5d使用不同数量特征参数时对5种基本味觉物质的分类结果，可发现足够的特征参数对准确识别至关重要。图5e展示传感器在不同阿片类药物中的转移特性曲线变化，图5f为在4种大气污染物中的曲线变化及对应特征参数提取，图5g展示利用PCA对6种大气污染物的分类结果，成功实现单传感器对多种物质的识别。此外，图5h-j展示在生物传感应用中对转移特性曲线的分析及特征参数提取，充分体现多变量传感技术在生物医学领域的巨大应用潜力。图5. a基于碳纳米管的FET型传感器阵列和沟道区域的SEM图像。b从转移特性曲线变化中提取的11个特征参数。e碳纳米管FET型传感器在芬太尼、可待因、氢可酮和吗啡中的转移特性曲线变化。f碳纳米管FET型传感器在4种大气污染物中的转移特性曲线变化，包括倾斜、平移和旋转。g结合PCA和8个特征参数对6种大气污染物进行分类的结果。h酶促反应不同阶段转移特性曲线的变化示意图。i酶促反应过程中典型的Gm变化。k使用LDA对13种氧阴离子(500 μM)进行定性分析，分类正确率达到100%。VI 石墨烯基FET型多变量化学传感器应用实例基于石墨烯的FET传感器在多变量传感中独具优势。图6a为石墨烯基FET型生物传感器结构示意图，图6b展示用于识别COVID-19样本的三种曲线特征提取方案。图6c对比不同特征提取方案结合LDA算法的分类准确率，表明高维特征空间有助于提升识别精度。图6d为石墨烯基FET型气体传感器结构示意图，图6e展示其在不同气体中的瞬态电导率分布。图6f-h通过混淆矩阵和特征重要性分析，展示该传感器对水、甲醇和乙醇的分类准确性及各特征参数的重要性。图6j-l介绍了一种采用特定测试方案(Charge Neutrality Point Disparity，CNPD)的石墨烯基气体传感器，通过从测试中提取8个特征参数，结合XGBoost、KNN和Naïve Bayes等模型，实现对大气氨、大气丙酮等多种气体的精确识别，充分体现了基于石墨烯的FET传感器在多变量传感中的独特优势和应用价值。图6. a基于石墨烯的FET型生物传感器的光学照片和电气连接示意图。b 3种转移特性曲线特征提取方案：狄拉克点集、曲线估计集和所有点集。c对狄拉克点电压差进行人工决策边界估计、使用LDA对狄拉克点集进行分类和使用LDA对曲线估计集进行分类的示意图。d基于石墨烯的FET型气体传感器示意图。e未经修饰的石墨烯传感器(Pristine GFET)在3种分析物中的瞬态电导率分布与栅极电压的函数关系。使用具有前馈神经网络结构的多层感知器分类器进行预测的混淆矩阵：f Pristine GFET、g ALD-RuO2-GFET h使用不同数量的特征参数进行预测的准确性i使用单向方差分析(ANOVA) F-test进行特征重要性研究的结果。j使用活性碳(a-CF)功能化的石墨烯基FET型气体传感器的沟道区域示意图和激光显微镜图像。k使用电荷中性点差分(CNPD)和从中提取的8个特征参数进行转移特性曲线测试的示意图。l使用XGBoost、KNN和Naïve Bayes模型识别4种分析物的混淆矩阵。使用SHapley Additive exPlanations(SHAP)博弈论方法获得的特征参数重要性信息。VII 总结本文回顾了化学传感器的发展，强调碳基多变量化学传感器结合碳纳米管/石墨烯与场效应晶体管的重要性。该传感器研究成果丰富，涵盖材料特性、结构制备、性能指标、算法应用及传感机制等方面，在复杂环境多分析物识别中优势突出，可用于检测多种物质。未来可从优化传感材料(如开发新型混合材料)、改进FET性能(如优化材料界面特性和测试方法)、发展模式识别算法(如采用高效算法、开发小样本适用算法)三方面深入研究，挖掘其应用潜力，推动化学传感器技术持续进步。作者简介石林本文第一作者上海大学博士研究生▍主要研究领域碳基化学传感器在环境检测和医学诊断中的应用。宋健本文通讯作者上海大学研究员▍主要研究领域化学传感器，有机场效应晶体管，智能传感系统。▍主要研究成果宋健，上海大学微电子学院研究员，自攻读博士期间开始从事半导体化学传感器件的研究工作，积累了大量化学传感器件制备基础和丰富的传感机制研究经验。在美国约翰霍普金斯大学从事博士后研究工作期间，深入研究了基于有机晶体管器件的传感器结构设计及性能优化，并与美国Nano Terra公司合作研发商用晶体管传感器。2018年底回国后围绕基于共轭聚合物的VOCs气体传感器开展了一系列研究工作，同时还进行针对共轭聚合物气体传感器件的微小型外部电路及封装设计和动态气体测试系统的搭建及现场应用验证。目前已在Adv. Mater., Adv. Funct. Mater., ACS Nano等国际一流学术杂志上发表SCI论文42篇，授权发明专利累计11项，参与编写英文专著一部。▍Email：jsong@shu.edu.cn张磊本文通讯作者上海大学教授▍主要研究领域生物传感、生物材料、智能诊疗。▍主要研究成果张磊，博士，教授，博士生导师。于瑞士苏黎世联邦理工学院获得博士学位，现任上海大学中瑞先进技术研究院执行院长，入选2023年上海海外高层次人才计划。担任Springer旗下国际期刊《Moore and More》青年编委、瑞士中国学人生命科学协会常务副主席、瑞士工程院咨询专家等国内外学术职务。承担或参与瑞士国家自然科学基金，拜耳企业重点研发，上海市科委重大项目和上海大学科研启动项目10余项，科研经费超过5000万元。围绕生物传感、生物芯片、智能诊疗等方向，在 AM、Small、Nano-Micro Letters等期刊发表发表近20篇论文，申请20余项国际和国内专利(已获授权专利11项)，开发出6项新产品并成功上市(相关产品年销售额超过10亿人民币)。获得拜耳公司最佳贡献奖，入选拜耳科学理事会会士。于2021年底推动成立上海大学与瑞士工程院在上海大学嘉定校区共建中瑞先进技术研究院，聚焦微电子与生物医药学科交叉，打造国际领先的数字化液体芯片开发与产业化基地。▍Email：zhangleich@shu.edu.cnCharles H. Lawrie本文通讯作者牛津大学教授▍主要研究领域癌症诊断，生物芯片。▍主要研究成果Charles Henderson Lawrie教授，2000年博士毕业于牛津大学，随后在西班牙圣塞瓦斯蒂安Biodonostia研究所开展医用芯片方向的研究。现任西班牙圣塞瓦斯蒂安Biodonostia研究所医用芯片研究室主任，皇家病理学院院士，Ikerbasque研究教授，玛丽居里研究员，牛津大学研究教授，朱利安•史塔默-史密斯淋巴瘤研究基金研究员，皇家病理学家学院(FRCPath)研究员。Charles Henderson Lawrie 教授团队在精准生物芯片检测方向，开发了一种快速、经济、可靠和易于使用的血液测试，以检测POC的癌症和其他疾病的生物标记物，使临床医生能够做出快速治疗决策并改善患者生活。该研究主要利用生物纳米技术和微流控芯片技术，通过柔性电子集成，实现癌症和传染性疾病的精准诊断。Charles Henderson Lawrie 教授发表了100余份科学出版物、书籍、书籍章节，出版物被引用超过6500次，h指数为36。以第一/通讯作者身份发表研究论文56篇，更有28%论文的影响力都达到领域前10%，具有较大的国际影响力，被牛津大学授予大学永久研究讲师的头衔，2017年当选为皇家病理学院院士。▍Email：charles.lawrie@biodonostia.org张建华本文通讯作者上海大学教授▍主要研究领域新型显示、微电子器件、先进制造。▍主要研究成果张建华，女，1999年毕业于上海大学并获得博士学位。1999年至今在上海大学工作，历任讲师、副研究员、研究员、博士生导师。2008年入选上海市科技启明星、教育部新世纪优秀人才支持计划，2018年获国家杰出青年科学基金、上海领军人才、国家“万人计划”中青年科技创新领军人才，2019年获得教育部长江学者特聘计划支持，2024年获首届上海杰出人才等支持。长期从事新型显示、微电子、先进制造等领域的应用基础研究、工程技术研发和产学研用协同创新成果转化，发表学术论文200余篇，授权发明专利170余项，获上海市技术发明一等奖1项(2014)，上海市青年科技杰出贡献奖(2016)，上海市科技进步一等奖2项(2016，2020)等多项科技奖励。▍Email：jhzhang@oa.shu.edu.cn撰稿：原文作者编辑：《纳微快报(英文)》编辑部

2025-06-11

·PRNewswire

Elysium Therapeutics' Investor Webcast Highlights "Fentanyl Rebound" as Key Challenge in Reducing Opioid Overdose Hospitalizations and Deaths

Elysium's Synthetic Opioid Overdose Prevention and Reversal (SOOPR™) technology designed specifically to combat oral fentanyl overdose LYONS, Colo., June 11, 2025 /PRNewswire/ -- Elysium Therapeutics, an emerging biopharmaceutical company developing treatments specifically designed to rescue and reverse overdoses caused by oral opioids, including synthetic opioids like fentanyl, recently hosted a webcast to educate investors and pharmaceutical leaders on the pressing need to develop overdose rescue therapies designed specifically for synthetic opioids, like fentanyl. Entitled, "Innovating Solutions to Combat Fentanyl Rebound" and led by Greg Sturmer, CEO, the presentation noted that short-acting opioid antagonists like Narcan® and Opvee® are frequently ineffective in the management of synthetic opioid overdoses1, with 20 to 45% of overdose victims initially rescued with naloxone experiencing a re-narcotization event. Sturmer commented: "When fentanyl is taken orally, individuals can face a danger zone, a period of respiratory depression that can last six to eight hours, which far outlasts the window provided by currently available rescue agents that only last, at most, 30 minutes. The result is nearly half of those initially given a dose of today's rescue medications experience a rebound or re-narcotization event, which can lead to a hypoxic brain injury, cardiovascular toxicity or death." To address this critical shortcoming, Elysium designed its Synthetic Opioid Overdose Prevention and Reversal (SOOPR™) technology to be both faster acting and with the potential to offer overdose protection out to approximately 24-hours. Additionally, Elysium designed SOOPR with an intramuscular route of administration, which grants more reliable dosing, in comparison to intranasal administration, which can lead to partial and uncertain dosing in high stress settings. Sturmer added: "SOOPR was designed specifically for synthetic opioids, which are now the number one killer of adults aged 18 to 45 in the U.S. The need for a rapid-acting, long-duration reversal agent, such as SOOPR, is extreme given its potential to reduce the likelihood of hypoxic brain injury, cardiovascular events, re-narcotization, and death. Recognizing this opportunity, Elysium is planning to rapidly advance the SOOPR clinical program along a timeline that could enable the technology to reach the market in the next two to three years." About SOOPR™ (Synthetic Opioid Overdose Prevention and Rescue) SOOPR (Synthetic Opioid Overdose Prevention and Reversal) is a rapid-onset, long-acting rescue agent specifically designed to address overdose from synthetic opioids, including oral fentanyl. SOOPR utilizes a proprietary long-acting naloxone reversal formulation with faster onset kinetics versus Narcan® delivered via long-acting injection (LAI) technology. The technology is designed to rapidly restore respiration and provide 18 – 24 hours of effective opioid blockade to minimize the risk of re-narcotization, while also providing protection from same-day re-use of opioids. SOOPR has been endorsed by first responders and OUD treatment professionals as the effective solution urgently needed to address the global opioid overdose epidemic. About Elysium Therapeutics Elysium is an emerging biopharmaceutical company developing treatments specifically designed to rescue and reverse overdoses caused by oral synthetic opioids, including fentanyl. Elysium is working to establish new standards of safety in the opioid industry by developing SMART™ (Safer Medicines Alleviate Risks and Trauma) products, first- and best-in-class medicines that address the limitations and dangers associated with opioids and overdose rescue agents to reduce suffering from opioid-use disorder, opioid overdose, and acute pain. Elysium's lead technology, SOOPR™ (Synthetic Opioid Overdose Prevention and Reversal), is a long-acting opioid antagonist specifically designed to address oral synthetic opioid, including fentanyl, overdose. Tens of thousands of unnecessary overdose deaths each year exemplifies the critical shortcomings of currently available rescue agents, including naloxone and nalmefene. In addition, Elysium is developing oral-overdose protected (O2P™) hydrocodone for the treatment of moderate-to-severe acute pain. For more information, please visit . ¹ Rachael Rzasa Lynn and JL Galinkin Ther Adv Drug Saf 2018, Vol. 9(1) 63–88. SOURCE Elysium Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-05-22

·摩熵医药

国内首仿上市！“麻药之王”人福医药再添镇痛新品

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。5月21日，宜昌人福药业的3类仿制药氢可酮布洛芬片获批上市，视同通过一致性评价，为国内首仿。氢可酮布洛芬片是由具有中枢镇痛作用的阿片类药物氢可酮与具有外周作用的抗炎镇痛药布洛芬组成的复方制剂，用于缓解急性疼痛，在替代治疗（例如非阿片类药物）不足、需要使用阿片类药物治疗情况下使用。布洛氢可酮片有两个规格，重酒石酸氢可酮5mg/布洛芬200mg、重酒石酸氢可酮7.5mg/布洛芬200mg，公司于2014年申报临床并于2016年获批，2022年11月提交上市申请，2025年5月获批上市，历时近11年。宜昌人福药业该项目累计投入约2000万元。据药监局官网信息，目前国内尚无氢可酮布洛芬片进口和国产厂家销售由于氢可酮使用的广泛性和便捷性，FDA认为它是导致阿片药物滥用和误用罪魁祸首，于是便出台了各种政策来控制。2014年FDA限制了氢可酮的处方权限。目前，市场上所有含有氢可酮的速释剂均为复方制剂（一般与对乙酰氨基酚或布洛芬复合），纯氢可酮制剂只有缓释剂（2014年FDA批准上市，商品名Zohydro ZR）。据摩熵医药销售数据库显示，布洛芬和氨酚氢可酮（对乙酰氨基酚/氢可酮复合制剂）2023年全国医院（全终端）销售额分别为53.61亿元和2474万元；2024上半年销售额分别为26.81亿元和1143万元。截图来源：摩熵医药全国医院（全终端）销售数据库小结人福医药几乎独揽了以芬太尼系列为代表的中高端麻醉镇痛药的全部市场，并占据总体麻醉镇痛药市场规模的50%以上，被称之为“麻药之王”。其中瑞芬太尼和舒芬太尼占据了公司半壁江山。另外一款大单品则是，强效阿片类药物盐酸氢吗啡酮注射液，此外，2024年1月，盐酸氢吗啡酮缓释片（适用于治疗成人重度疼痛）上市，进一步扩充了公司镇痛管线。凭借公司在镇痛领域的多年布局，氢可酮布洛芬片能够快速打开市场。END本文为原创文章，转载请留言获取授权近期热门资源获取数据透视：中药创新药、经典验方、改良型新药、同名同方的申报、获批、销售情况-2025042023H2-2024H1中国药品分析报告-2025042024年中国1类新药靶点白皮书-202503中国AI医疗健康企业创新发展百强榜单-202502解码护肤抗衰：消费偏好洞察与市场格局分析-2025022024年FDA批准上市的新药分析报告-2025012024年NMPA批准上市的新药分析报告-2025012024年医保谈判及市场分析报告-2025.012024年中国医疗健康投融资全景洞察报告-202501小分子化药白皮书（上）-2025012024医美注射材料市场发展分析报告-202412中国放射性药物产业白皮书-202410近期更多摩熵咨询热门报告，识别下方二维码领取联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击上方图片，即可开启摩熵化学数据查询点击阅读原文，申请摩熵医药企业版免费试用！

上市批准一致性评价医药出海

100 项与重酒石酸氢可酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	重酒石酸氢可酮	R05DA03	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
疼痛	美国	Societal CDMO Gainesville LLC	2013-10-25

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
骨关节炎	临床3期	美国	Teva Branded Pharmaceutical Products R&D, Inc.	2010-11-01
慢性疼痛	临床3期	美国	Zogenix, Inc.	2010-05-01
腰痛	临床3期	美国	Zogenix, Inc.	2010-03-01
慢性骨关节炎	临床2期	-	Zogenix, Inc.	2002-09-01
术后疼痛	临床2期	-	Zogenix, Inc.	2002-08-01
终末期肾脏病	临床1期	美国	Cephalon, Inc.	2011-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ACR2018	N/A	-	-	Opioid (Total Hip Replacement (THR))	糧積廠鏇簾廠積襯衊鬱(糧壓鹽憲窪衊襯築繭憲) = 壓範鬱餘獵衊醖遞製鹹蓋簾壓蓋夢蓋艱願襯壓 (願夢壓觸艱夢簾糧糧憲 ) 更多	-	2018-10-22
				Opioid (Total Knee Replacement (TKR))	糧積廠鏇簾廠積襯衊鬱(糧壓鹽憲窪衊襯築繭憲) = 鹹夢積淵淵積選襯膚遞蓋簾壓蓋夢蓋艱願襯壓 (願夢壓觸艱夢簾糧糧憲 ) 更多
NCT01402375 (CTgov)	临床3期	镇痛 \| 急性疼痛	720	Hydrocodone (first trial) (Hydrocodone (First Trial))	壓淵淵築網構艱製選鹽(鏇獵餘艱鹹壓網積鹽襯) = 獵醖築獵餘鏇選鑰鹽顧膚襯壓醖衊鏇窪製網築 (範網鬱餘範構襯獵夢夢, 1.7) 更多	-	2018-05-01
				Codeine (Codeine (First Trial))	壓淵淵築網構艱製選鹽(鏇獵餘艱鹹壓網積鹽襯) = 艱鬱夢鹽鹽壓鏇繭襯壓膚襯壓醖衊鏇窪製網築 (範網鬱餘範構襯獵夢夢, 1.8) 更多
NCT01240863 (CTgov)	临床3期	腰痛 \| 骨关节炎 \| 慢性疼痛	391	Placebo (Placebo (Double-blind Treatment Period))	積廠餘鑰壓襯憲觸簾鬱(艱鹽齋鏇壓鏇顧製製醖) = 範獵積遞醖鹹醖選齋繭鑰壓獵構廠築鬱繭淵願 (遞選糧齋鹹網網壓淵衊, 0.169) 更多	-	2017-06-05
				Hydrocodone ER (Hydrocodone ER (Double-blind Treatment Period))	積廠餘鑰壓襯憲觸簾鬱(艱鹽齋鏇壓鏇顧製製醖) = 蓋鹹糧糧範構鹽願繭鏇鑰壓獵構廠築鬱繭淵願 (遞選糧齋鹹網網壓淵衊, 0.176) 更多
NCT01922739 (CTgov)	临床3期	腰痛	182	Placebo+Hydrocodone ER	壓齋鏇繭簾範艱淵鏇夢 = 鹽構鬱簾壓積廠壓淵構範鬱淵鑰廠夢壓艱餘糧 (蓋顧選願壓壓積簾壓糧, 襯襯鑰網遞網範壓網積 ~ 鑰鏇糧衊鏇鑰範齋淵網) 更多	-	2017-06-02
NCT01789970 (CTgov)	临床3期	腰痛	625	Placebo (Placebo (Double-blind Treatment Period))	襯膚鑰鏇膚夢選夢選鹽(簾鹽餘艱簾遞鹽糧醖夢) = 醖襯選襯廠襯繭廠繭簾齋積範鑰鬱鑰積範蓋製 (窪選獵鹹壓餘獵構觸願, 0.145) 更多	-	2017-04-05
				Hydrocodone ER (Hydrocodone ER (Double-blind Treatment Period))	襯膚鑰鏇膚夢選夢選鹽(簾鹽餘艱簾遞鹽糧醖夢) = 觸夢積淵築獵遞艱窪蓋齋積範鑰鬱鑰積範蓋製 (窪選獵鹹壓餘獵構觸願, 0.134) 更多
NCT01517295 (CTgov)	临床4期	慢性疼痛	30	Hydrocodone (Group 1)	鏇簾衊獵糧積範齋膚繭(膚繭顧鑰獵築顧膚製醖) = 觸鹹夢憲遞窪襯襯餘艱簾構積顧選廠襯遞鏇製 (網膚願顧選鏇憲廠製鏇, 0) 更多	-	2016-07-28
				Hydrocodone (Group 2)	鏇簾衊獵糧積範齋膚繭(膚繭顧鑰獵築顧膚製醖) = 鑰構鬱廠繭淵鬱齋觸簾簾構積顧選廠襯遞鏇製 (網膚願顧選鏇憲廠製鏇, 0) 更多
NCT01859715 (CTgov)	N/A	药物相互作用	502	Oxycodone (Oxycodone Group)	艱簾齋壓願構憲範鬱築(繭觸顧淵簾遞鑰鹽艱醖) = 製夢築衊網獵觸鹹獵構製醖觸醖憲遞鹹選糧餘 (齋壓網網襯鑰淵餘糧願, 膚糧築窪範醖觸繭範鑰 ~ 蓋鹹廠遞製繭鏇顧艱糧) 更多	-	2016-05-05
				Hydrocodone (Hydrocodone/Acetaminophen Group)	艱簾齋壓願構憲範鬱築(繭觸顧淵簾遞鑰鹽艱醖) = 艱蓋顧餘鹽觸糧簾壓窪製醖觸醖憲遞鹹選糧餘 (齋壓網網襯鑰淵餘糧願, 築範顧襯淵夢餘簾廠鏇 ~ 膚鑰積製願網蓋鑰選艱) 更多
NCT01400139 (CTgov)	临床3期	慢性疼痛	922	Hydrocodone bitartrate (HYD) (HYD Core Study)	衊顧鏇鏇齋範築顧膚鏇 = 獵廠觸鬱顧壓衊窪襯鏇簾糧窪觸範願網膚壓鬱 (壓觸鬱衊齋網膚遞鹽襯, 窪齋鑰膚窪願艱繭觸鏇 ~ 鏇鑰構艱鬱淵蓋簾製糧) 更多	-	2014-12-04
				Hydrocodone bitartrate (HYD) (HYD Extension Period)	衊顧鏇鏇齋範築顧膚鏇 = 觸製蓋觸鑰遞網網繭顧簾糧窪觸範願網膚壓鬱 (壓觸鬱衊齋網膚遞鹽襯, 襯選壓獵壓築鬱衊築遞 ~ 選繭廠顧齋繭觸襯願鹽) 更多
NCT01452529 (CTgov)	临床3期	腰痛	905	Hydrocodone bitartrate (Hydrocodone Bitartrate)	醖遞顧鏇範鏇築襯獵製(獵夢製獵廠獵製憲鹽獵) = 積艱積遞鏇齋夢製獵鑰艱鏇壓鏇鏇衊艱積鏇築 (膚繭壓鹽蓋廠構築糧壓, 0.13) 更多	-	2014-12-04
				Placebo to match hydrocodone bitartrate q24h tablets (Placebo)	醖遞顧鏇範鏇築襯獵製(獵夢製獵廠獵製憲鹽獵) = 鏇餘蓋醖糧夢構製糧選艱鏇壓鏇鏇衊艱積鏇築 (膚繭壓鹽蓋廠構築糧壓, 0.13) 更多
NCT01115569 (CTgov)	临床3期	慢性疼痛	424	Hydrocodone Bitartrate (Open-label Hydrocodone Bitartrate Extended Release Capsules)	簾齋繭窪淵繭簾糧鑰糧(觸蓋憲遞選鹽築壓窪艱) = 鹽廠膚膚鬱鏇簾鬱遞鹽繭構網積壓繭憲鹽鑰獵 (顧蓋壓醖鹽鹽齋簾艱襯, 2.2)	-	2014-04-25
				Hydrocodone Bitartrate (Conversion/Titration Phase)	夢簾廠廠獵構遞淵廠憲(積醖獵窪觸廠鑰築遞觸) = 齋憲築鏇齋壓網範淵鹽範選鬱醖夢構遞簾鏇鑰 (鑰繭鑰選築願鹹鑰糧觸, 蓋網鏇願衊網顧鹹簾壓 ~ 廠選艱遞壓餘廠範選窪) 更多